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Promoter methylationWe studied promoter methylation (PM) of 11 genes in Peripheral Blood Lymphocytes (PBLs)
and tissues of hepatitis C virus (HCV) associated hepatocellular carcinoma (HCC) and chronic
hepatitis (CH) Egyptian patients. The present study included 31 HCC with their ANT, 38 CH
and 13 normal hepatic tissue (NHT) samples. In all groups, PM of APC, FHIT, p15, p73, p14,
p16, DAPK1, CDH1, RARb, RASSF1A, O6MGMT was assessed by methylation-speciﬁc PCR
(MSP). APC and O6-MGMT protein expression was assessed by immunohistochemistry (IHC)
in the studied HCC and CH (20 samples each) as well as in a different HCC and CH set for
conﬁrmation of MSP results. PM was associated with progression from CH to HCC. Most
genes showed high methylation frequency (MF) and the methylation index (MI) increased with
disease progression. MF of p14, p73, RASSF1A, CDH1 and O6MGMT was signiﬁcantly higher
in HCC and their ANT. MF of APC was higher in CH. We reported high concordance between
MF in HCC and their ANT, MF in PBL and CH tissues as well as between PM and protein
expression of APC and O6MGMT. A panel of 4 genes (APC, p73, p14, O6MGMT) classiﬁes
the cases independently into HCC and CH with high accuracy (89.9%), sensitivity (83.9%)
and speciﬁcity (94.7%). HCV infection may contribute to hepatocarcinogenesis through
enhancing PM of multiple genes. PM of APC occurs early in the cascade while PM of p14,
p73, RASSF1A, RARB, CDH1 and O6MGMT are late changes. A panel of APC, p73, p14,
O6-MGMT could be used in monitoring CH patients for early detection of HCC. Also, we
28 A.-R.N. Zekri et al.found that, the methylation status is not signiﬁcantly affected by whether the tissue was from
the liver or PBL, indicating the possibility of use PBL as indicator to genetic proﬁle instead
of liver tissue regardless the stage of disease.
ª 2014 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common so-
lid tumor worldwide and the fourth leading cause of cancer-re-
lated death [1]. It accounts for approximately 600,000 deaths
per year [2] and it shows a wide geographical variation with
low incidence areas in North America and Europe, and high
incidence areas in Africa and Asia. In Egypt the incidence of
HCC has doubled in the past 10 years, thus it is now the sec-
ond most incident and lethal cancer in men after lung cancer
[3]. The heavy burden of HCC parallels the high rates of
HCV infection while hepatitis B virus (HBV) rates have de-
clined after the introduction of the vaccine in 1992 [4,5].
Although it has been estimated that 80% of HCC occurs in cir-
rhotic livers, the exact molecular mechanisms underlying virus-
associated hepatocarcinogenesis are still unclear.
Multiple genetic aberrations of oncogenes and tumor sup-
pressor genes have been identiﬁed, which control hepatocytes
proliferation, differentiation, maintenance of genomic integrity
and death [6,7]. In addition, recent studies suggest aberrant
DNA (PM) as an alternative mechanism of tumor pathogene-
sis because the hypermethylated promoters often lack tran-
scriptional activity, which could result in gene inactivation
[8]. DNA methylation refers to the addition of a methyl group
to the cytosine residue in CpG dinucleotides. Normally, clus-
tered CpG dinucleotides (CpG islands) are not methylated
regardless of their transcriptional status, whereas in tumor
cells, methylation of CpG islands in the promoter regions of
many tumor suppressor genes (TSGs) and growth regulatory
genes effectively silences those genes. Since different types of
cancer show distinct DNA methylation proﬁles, it is possible
to develop cancer- type speciﬁc methylation signatures [9].
The power of PM as a marker derives not only from its ability
to be detected in a wide variety of samples, from fresh speci-
mens to body ﬂuids and archival parafﬁn-embedded tissues,
but also from the deﬁned localization of the lesion in promoter
CpG islands of the genes. This could be an early important
event in carcinogenesis and could also be of importance for
treatment or prognostication [10]. DNA methylation proﬁles
in Egypt has not been well studied, though it has the highest
prevalence of HCV infection in the world with approximately
14% of the population infected, and seven million have
chronic HCV induced liver disease [11].
We sought to assess DNA methylation patterns in Egyptian
patients with HCV associated chronic hepatitis and HCC using
a panel of genes that are commonly hypermethylated in other
solid tumors (p14, p15, p16, p73, APC, FHIT, DAPK1, CDH1,
RARb, RASSF1A, and O6MGMT) in order to understand the
role of epigenetic silencing in this patient population. The stud-
ied groups included 38 HCV/genotype-4-associated CH pa-
tients with matched PBL in 20 of them and 31 HCC cases
with their ANT. Thirteen NHT obtained from healthy individ-
uals, were used as a control group. The prognostic impact of
aberrant PM was also assessed through correlations betweenmethylation patterns and the clinic-pathological features of
the studied patients.Methodology
Study design
This prospective study encompassed three groups. The ﬁrst
group included 31 HCC cases, of which, 23 cases had enough
adjacent normal tissue (ANT) samples to be assessed. The
second group included: A) 20 cases of chronic CH patients
with cirrhosis from which tissue samples and Peripheral
Blood Lymphocytes (PBLs) were collected and 18 cases of
asymptomatic carriers (ASC), from which tissue samples only
were collected. The third group was a control group in which
normal hepatic tissue (NHT) samples were obtained from 13
liver transplantation donors matched for age (±5 years) and
sex.
HCC samples were obtained from patients who underwent
surgical resection of their tumors at the National Cancer Insti-
tute (NCI), Cairo, Egypt. Whereas CH samples were obtained
from the Endemic medicine department, Kasr Al-Aini School
of Medicine, Cairo University. All cases were assessed for viral
proﬁle as a part of the routine clinical workup. All HCC and
CH cases were positive for HCV/genotype-4 and negative for
HBV by serological tests and/or HBV-DNA by real time
PCR (qRT PCR). Histopathological diagnosis and grading
of the HCC cases were done according to the World Health
Organization (WHO) classiﬁcation criteria [12] and staging
was performed according to the American Joint Committee
on Cancer [13]. Grading and staging of CH patients were per-
formed according to the pathology activity index [14]. A writ-
ten informed consent was obtained from each patient and the
Institutional Review Boards of the National Cancer Institute
and Kasr Al-Aini School of Medicine, Cairo University, re-
viewed the study protocol which was in accordance with the
2007 Declaration of Helsinki. All patients’ characteristics were
collected from the patients’ records and illustrated in Table 1.
DNA extraction
DNA was extracted from PBL according to standard proto-
cols (6). Brieﬂy, equal volume of equilibrated phenol (pH
7.0–7.5) was added to samples and vortexed. The upper aque-
ous layer was removed and an equal volume of phenol/chloro-
form (1:1) was added and vortexed. The upper aqueous layer
was removed again and an equal volume of chloroform/iso-
amyl alcohol (24:1) was added and vortexed. This was fol-
lowed by the addition of 3 M Sodium acetate (pH 4.7–5.2),
DNA precipitation by ice-cold ethanol and overnight incuba-
tion at 80 C. The ﬂuid was decanted and the DNA pellet
was dissolved in sterile water. DNA was extracted from fresh
tissue samples as previously described [15].
Table 1 Clinical features of the studied groups.
Variables CAH cases (38) HCC cases (31) p Value
Mean Range Mean Range
Age (years) 40.0 (1–61) 57 (38–78) <0.0001
WBCs 5.9 (3.2–108) 5.4 (2.5–26.6) <0.0001
RBCs 14 (4.17–15.5) 4.2 (3.6–9.3)
HG 14.7 (11.3–17) 13.1 (9.3–16.9) <0.0023
Platelets 202.5 (98–377) 195 (33–356) <0.0001
AST 48.5 (14–297) 67 (7–432)
ALT 52 (4–209) 58 (10–480)
Alk 90 (34–282) 96 (35–387)
Albumin 4.3 (2.6–40) 3.3 (2.5–6.0)
Total bilirubin 0.99 (0.28–23.4) 1.00 (0.20–4.1)
Direct bilirubin 0.55 (0.1–12.1) 0.4 (0.2–2.6)
Only signiﬁcant p values are illustrated.
HCC and Methylation 29Bisulphate conversion and methylation-speciﬁc polymerase chain
reaction (MSP)
The extracted DNA was subjected to bisulfate treatment fol-
lowed by MSP using the primer sequences and the methyla-
tion-speciﬁc PCR conditions illustrated in Table 2. DNA
methylation of CpG islands for p14, p15, p16, p73, APC,
FHIT, DAPK1, CDH1, RARb, RASSF1A and O6MGMT
genes was determined using speciﬁc primers for methylated
(M) and unmethylated (UM) DNA [16]. Negative control sam-
ples without DNA were included in each set of PCR. PCR
products were analyzed on 4% ethidium bromide-stained aga-
rose gels and visualized under ultraviolet illumination (Fig. 1).
Immunohistochemistry
Protein expression of APC and O6MGMT was assessed in 20
cases of HCC and 20 cases of CH which were assessed for PM
by MSP as well as in a conﬁrmatory set of 107 HCC, 52 CH
cases and 40 NHT samples to conﬁrm the results of the MSP
using the tissue microarray (TMA) technique. Two (5 lm) thick
sections were obtained from each TMA block on positive
charged slides to be used for immunohistochemistry. Sections
were deparafﬁnized, rehydratedin graded alcohols and the stan-
dard streptavidirin–biotin–peroxidase technique was per-
formed [17] using the following antibodies: rabbit anti-human
O6MGMT (EPR-4397, Epitomics, USA 1:100) and the rabbit
anti-humanAPC (EP-701Y, Epitomics, USA 1:50).Antigen re-
trieval was performed bymicrowave pretreatment in 0.01 M cit-
rate buffer (pH 7.4) and then the primary antibody was applied
and incubated overnight at 4 C in a humidiﬁed chamber. After
three washes in PBS, the secondary antibody and the avidin–
biotin complex (ABC) were applied to slides with diaminobenzi-
dine (DAB) as a chromogen and Mayer’s hematoxylin as a
counterstain. To evaluate the speciﬁcity of the antibodies,
known positive and negative tissues were used as controls.
Assessment was based on a cytoplasmic staining pattern for
APC and on nuclear expression for O6MGMT.
Statistical methods: The data comprised of information
about the presence or absence of PM of the 11 genes in four
distinct groups, HCC (31) T, CH with cirrhosis (20) C, ASC
(18) A, and healthy controls (NHT, n= 13) B. In the HCC
group, 23 HCC cases had data for the tumor and the ANT
whereas the remaining eight cases, had data for the tumorand the corresponding PBL but not on ANT. In the CH
group, data for tissues was paired with the corresponding
PBL. We used one-way ANOVA test to detect differences in
the available clinicopathological variables between disease
states. For each of these variables, the corrected p-values were
reported. Logistic regression with a random effect analysis
(non-linear mixed model) was used to determine differences
across categories within a group and methylation status con-
trolling for the subject effect for CH and HCC groups. Logistic
regression analysis (Proc Logistic) was used to determine dif-
ferences in methylation status and we reported the interaction
and the main effects. The interaction effects measure any syn-
ergistic or antagonistic effect of the methylation status (meth-
ylated versus unmethylated) and the disease site (normal or
tumor and liver or PBL); disease state (healthy controls,
ASC, CH with cirrhosis or HCC). All statistical tests were per-
formed using the SAS software package (version 9.2, SAS,
Cary, NC).Results
Clinical ﬁndings
There was a signiﬁcant difference (corrected for multiplicity)
between the studied groups regarding age (p-value <0.0001),
HG (p value <0.0023), platelets (p value <0.0001) and WBCs
(p value <0.0001). In all cases, the HCC group was signiﬁ-
cantly different from CH patients with cirrhosis and the
asymptomatic carrier groups as in Table 1.
Methylation index (MI)
Calculation of the MI (deﬁned as the ratio between the number
of methylated genes and the number of total genes analyzed
for each sample) was done for all cases. The MI ranged from
0 to 0.55 in CH cases (average: 0.27), and from 0.27 to 0.90
in HCC (average: 0.36). The difference between both groups
was statistically insigniﬁcant (p> 0.05).
DNA methylation in normal hepatic tissues
PM of the 11 tested genes was assessed in 13 NHT samples.
None of the samples showed PM of p15, p73, RARb, RASS-
Table 2 Primers sequences and conditions of the methylation speciﬁc PCR (MSP).
Gene Primers Annealing temperature (1C) MgCl2 Cycles
CDH1 (M) TAATTAGCGGTACGGGGGGC CGAAAACAAACGCCGAATACG 59 4.5 32
CDH1 (U) TTAGTTAATTAGTGGTATGGGGGGTGG ACCAAACAAAAACAAACACCAAATACA 59 4.5 32
DAPK (M) GGATAGTCGGATCGAGTTAACGTC CCCTCCCAAACGCCGA 59 4.5 35
DAPK (U) GGAGGATAGTTGGATTGAGTTAATGTT CAAATCCCTCCCAAACACCAA 59 4.5 35
p73 (M) GGACGTAGCGAAATCGGGGTTC ACCCCGAACATCGACGTCCG 64 4.5 35
p73 (U) AGGGGATGTAGTGAAATTGGGGTTT ATCACAACCCCAAACATCAACATCCA 60 4.5 35
O6O6-MGMT (M) TTTCGACGTTCGTAGGTTTTCGC GCACTCTTCCGAAAACGAAACG 56 3.5 35
O6O6-MGMT (U) TTTGTGTTTTGATGTTTGTAGGTTTTTGT AACTCCACACTCTTCCAAAAACAAAACA 57 4.5 35
p14 (M) GTGTTAAAGGGCGGCGTAGC AAAACCCTCACTCGCGACGA 54 4.5 35
p14 (U) TTTTTGGTGTTAAAGGGTGGTGTAGT CACAAAAACCCTCACTCACAACAA 56 4.5 35
p15 (M) GCGTTCGTATTTTGCGGTT CGTACAATAACCGAACGACCGA 57 3.5 35
p15 (U) TGTGATGTGTTTGTATTTTGTGGTT CCATACAATAACCAAACAACCAA 59 4.5 35
p16 (M) TTATTAGAGGGTGGGGCGGATCGC CCACCTAAATCGACCTCCGACCG 68 1.5 33
p16 (U) TTATTAGAGGGTGGGGTGGATTGT CCACCTAAATCAACCTCCAACCA 58 4.5 33
FHIT (M) TTGGGGCGCGGGTTTGGGTTTTTACGC CGTAAACGACGCCGACCCCACTA 71–63 1.5 32
FHIT (U) TTGGGGTGTGGGTTTGGGTTTTTATG CATAAACAACACCAACCCCACTA 64 1.5 33
APC (M) TATTGCGGAGTGCGGGTC TCAACGAACTCCCGACGA 62 3.5 35
APC (U) GTGTTTTATTGTGGAGTGTGGGTT CCAATCAACAAACTCCCAACAA 62 1.5 35
RASSF1A (M) TTCGTCGTTTAGTTTGGATTTTG CCGATTAAACCCGTACTTCG 56 1.5 35
RASSF1A (U) TGTTGTTTAGTTTGGATTTTGG TACAACCCTTCCCAACACAC 59 3.5 35
RARb (M) TCGAGAACGCGAGCGATTCG GACCAATCCAACCGAAACGA 62 1.5 35
RARb (U) TTGAGAATGTGAGTGAATTGA AACCAATCCAACCAAAACAA 59 1.5 35
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Fig. 1 Methylation-speciﬁc PCR analyses of nine representative HCC samples (labeled 1–9 on the top). Each gene is indicated on the
right. Both methylated (M) and unmethylated (U) reactions were ampliﬁed for each bisulﬁte-treated DNA and run in a 4% agarose gel.
HCC and Methylation 31F1A or O6MGMT. PM of the p14 was detected in 46.2% of
the cases followed by APC, which was methylated in 30.8%
of the cases. A signiﬁcant difference in methylation frequency
(MF) between NHT and CH groups was reported for APC,
FHIT, DAPK and RASSF genes as shown in Fig. 2 and
Table 3.
Analysis of signiﬁcant difference of DNA methylation within the
CAH group
To understand aberrant DNA methylation of the selected 11
genes in CAH group (n= 38) to determine whether there are
differences within CAH-tissues and CAH-PBL groups across
the methylation proﬁles, data were analyzed according to b
analysis approach (Generalized Linear Mixed Models) correct-
ing for multiplicity using a Bonferroni adjustment. Our results
as shown in Fig. 3A–K indicate that there are no interaction ef-
fects between methylation status and disease site among
groups. This means that methylation status is not signiﬁcantly
affected by whether the tissue was from the liver or from the
PBL. However, statistical values for APC (Fig. 3A; p-va-
lue = 0.03) and p16 (Fig. 3F; p-value = 0.04) would be con-
sidered signiﬁcant for the un-adjusted criteria. There are
signiﬁcant differences between methylated and unmethylated
states for APC, p14, p73, p16, DAPK1, and RASSF1A. None
of the genes were different across tissue and PBL groups, albeit
APC had a p-value of 0.04. The interaction in APC (Fig. 3A) is
evidenced by the change from 0.95 to 0.10 from methylated tounmethylated state for the chronic liver tissue and a smaller
change of 0.80–0.40 from methylation to unmethylation for
the PBL group.Analysis of Signiﬁcant difference of DNA methylation with
HCC groups
To understand aberrant DNA methylation of the selected 11
genes in HCC, we followed the same technique of data analysis
as with CAH group to determine DNA methylation status of
genes in 31 HCCs and their adjacent non-cancerous tissues.
We used a Bonferroni correction with 0.0045 (.05/11) as our
cut-off for signiﬁcance. Our results indicate that there are no
interactions among the tissue sites and methylation status for
any of the genes. As shown in Fig. 4A–K, there were differ-
ences in the methylation status for the genes RASSF1A
(Fig. 4I), FHIT (Fig. 4B), APC (Fig. 4A), p14 (Fig. 4E), p73
(Fig. 4C), RARb (Fig. 4H), O6MGMT (Fig. 4J), and DAPK1
(Fig. 4G). None of the genes showed much difference across
the disease sites of cancerous and non-cancerous tissue though
p16 (Fig. 4F), it showed the smallest p-value of 0.072, which is
not considered as signiﬁcant by our criterion.Analysis of DNA methylation status across the disease groups
Across group differences among the four groups enrolled
(HCC, CAH, ASC, NHT) were analyzed using binary logistic
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Fig. 2a Methylation of 11 genes in hepatocellular carcinoma
patients. \ Dark squares depict methylation and blank squares
depict unmethylation.
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Fig. 2b Methylation of 11 genes in patients with chronic liver
diseases. \ Dark squares depict methylation and blank squares
depict unmethylation.
32 A.-R.N. Zekri et al.regression in PROC LOGISTIC for each gene. Our results
indicate that there is a signiﬁcant interaction between disease
state (groups) and DNA methylation of genes (Fig. 5A–K,).
As shown in Fig. 4A, there is a signiﬁcant group effect for
APC (ASC group is different from HCC Group, p-va-
lue = 0.0006). As can be seen from the graph, the interaction
is explained by the fact that there is a bigger difference between
methylation and un-methylation for the CH group than any of
the other groups especially the NHT. For DAPK1 (Fig. 5G),
there is a marginal group effect, not signiﬁcant by our cor-
rected level of p value = 0.004 (NHT is different fromHCC
p value = 0.007) and RARb (Fig. 5H) (NHT is different from-
HCC Group p-value = 0.007). In contrast, there are signiﬁ-
cant methylation effects for APC (p-value <0.0001), FHIT
(p-value <0.0001), p15, (p-value = 0.003), p14 (p-value
<0.0001), DAPK1 (p-value <0.0001), RARb (p-value
<0.0001) and E-cadherin (p-value <0.0001).Analysis of methylation coordination
Coordination of methylation at the 11 tested genes was ana-
lyzed by the Mann–Whitney U test through comparing the sta-
tus of each gene (M or U) with the MI calculated with the
remaining genes. A summary of methylation results and con-
cordance tests of each locus in HCC patients is shown in Ta-
ble 4 and Fig. 2. The combined effect of the studied
methylated genes as biomarkers for diagnosis of HCC and
CAH has also been studied. When all signiﬁcant variables were
entered into the stepwise logistic regression, only APC, p73,
p14, O6MGMT independently affected the classiﬁcation of
cases into HCC and CH as in Table 5. These four genes com-
bined give an accuracy of 89.9%, sensitivity 83.9% and speci-
ﬁcity 94.7%.
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HCC and Methylation 33Immunohistochemistry
Protein expression of two of APC and O6MGMT was as-
sessed in 20 NHT samples, 20 HCC and 20 CH tissues as well
as in an additional set of samples including 40 NHT, 52 CH
and 107 HCC tissue samples for conﬁrmation of the methyl-
ation results. In the original set, cytoplasmic immunostaining
for the APC protein was detected in 11 (55%) NHT, with loss
of staining in 10 (50%) CH, and 15 (75%) HCC. As for the
conﬁrmatory set, we were able to detect cytoplasmic immu-
nostaining for the APC protein in 20 (50%) NHT, with loss
of staining in 30 (57.7%) CH, and 77 (72%) HCC tissues. On
the other hand, nuclear immunostaining for O6MGMT pro-
tein was detected in 13 (65%) NHT with loss of expression in
11(55%) CH and 16 (80%) HCC of the original set. While in
the conﬁrmatory set O6MGMT protein were lost in 26 (50%)
CH and 70 (65.4%) HCC cases (Fig. 6).
Discussion
Changes in DNA methylation patterns of TSGs play a role in
the development and progression of many tumor types. How-
ever, data regarding HCC show wide variability in the results
that could be attributed to several factors including the
underlying etiologic factor(s) [18,19]. Our study is the ﬁrst
to assess the role of DNA PM of a well selected panel of
genes in clinical samples obtained from a cohort of patient
population infected with HCV/genotype 4 in an attempt to
understand their impact on disease progression.
We have previously reported a high methylation fre-
quency of APC, FHIT, CDH1 and p16 in the plasma and tis-
sues of 28 HBV and HCV-associated HCC patients from
Egypt [15]. Therefore, we sought to conﬁrm this data in a lar-
ger cohort of HCV- genotype 4 infected patients, including
asymptomatic carriers, CH with cirrhosis and HCC using
11 genes that are commonly hypermethylated in several tu-
mor types. We determined several differentially methylated
genes both in liver tissues and PBL that represent the progres-
sion from NHT to CH and HCC in HCV genotype 4-infected
persons. We also identiﬁed a panel of genes (APC, p73, p14,
O6MGMT) that can independently affect the classiﬁcation of
cases into HCC and CH with 89.9% accuracy, 83.9% sensi-
tivity and 94.7% speciﬁcity.
Fig. 3 Differences across methylation proﬁles within CAH\ cases between tissues and PBL.
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Fig. 4 Differences across methylation proﬁles between HCC\ cases and their ANT# samples with 0.0045 as a cut-off for signiﬁcance.
* HCC= T. # ANT= N.
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Fig. 5 Differences in the methylation frequency among the four studied groups. (T = HCC, C = CAH with cirrhosis,
A = asymptomatic carrier and B = normal hepatic tissue).
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Fig. 5 (continued)
HCC and Methylation 37A high methylation frequency was reported for all studied
genes, except for p15, in the PBL and tissues with increasing
MI as the disease progresses. Our data regarding the p15 gene
conﬁrms our previous study where p15 methylation was re-
ported in 14.2% only of HCC cases [15]. Within the studied
groups, the methylation frequency of p14, p73, RASSF1A
and O6MGMT was signiﬁcantly higher in HCC and their
ANT compared to CH and the NHT samples whereas PMof APC was signiﬁcantly higher in CH patients. This applied
to PBL and tissues except for RASSF1A and O6MGMT, where
the difference in methylation frequency in PBL was statistically
insigniﬁcant. The high methylation frequency reported here
conﬁrms the results of some previous studies including that
of Archer [20] who found a high methylation frequency of their
studied genes in HCV-associated HCC compared to HBV-
associated cases or to NHT. They concluded that the virus
Table 4 Summary of methylation speciﬁc PCR results and
concordance tests of each locus in HCC samples.
Factor Concordance Kappa# p-Value*
n= 31
n (%)
APC 28 (90.3) 0.803 <0.001
FHIT 24 (77.4) 0.497 0.006
P15 31 (100.0) 1.000 <0.001
P73 18 (58.1) 0.248 0.150
P14 31 (100.0) 1.000 <0.001
P16 24 (77.4) 0.558 0.001
DAPK 22 (71.0) 0.318 0.076
RARb 27 (87.1) 0.431 0.012
RASSF 31 (100.0) – –
O6O6-MGMT 26 (83.9) 0.640 <0.001
CDH1 22 (71.0) 0.425 0.016
– Numbers are too small for a valid statistical analysis.
# Kappa measure of agreement.
* p-Values 6 0.05 are considered signiﬁcant.
Table 5 Stepwise logistic regression for HCC.
Parameter Regression
estimate
p-Value Odds
ratio
95% CI for OR
APC 3.606 0.003 0.027 0.003 0.287
p73 3.671 0.001 39.302 4.752 325.017
P14 3.638 0.009 38.014 2.492 579.829
O6-MGMT 2.589 0.014 13.311 1.685 105.132
38 A.-R.N. Zekri et al.may induce accelerated hypermethylation even in the early
stages of infection, which can subsequently lead to tumor
development.
RASSF1A, a candidate TSG, frequently shows hyperme-
thylation and loss of heterozygosity with consequent gene
silencing in several human cancers [21]. In HCC, PM of RASS-
F1A gene was reported in 78–95% of the studied cases [22–24].
Our results are comparable to these studies since RASSF1A
methylation was detected in all HCC and in 68.4% CH cases
(second only to APC). Our results are also comparable to Gio-
ia et al. [25] who reported an increase in RASSF1A methyla-
tion with progression from regenerative conditions (cirrhosis)
to hepatocellular nodules and HCC as well as with Chan
et al. [26] who reported RASSF1A methylation in the blood
and tissues of HCC patients.
Within the identiﬁed panel of genes that independently af-
fected the classiﬁcation of cases into HCC and CH in this
study, p14 showed a high methylation frequency in HCC cases.
Our data conﬁrms those of Anzola et al. [27] and Yang et al.
[28] who demonstrated that p14 PM is associated with the
pathogenesis of HCC and suggested that inactivation of p14
through PM could be an important mechanism for HCV-in-
duced HCC. The fact that we were able to detect PM of the
p14 gene in NHT as well as in CH with almost the same fre-
quency suggests that it might be an early event during the cas-
cade of HCV-induced HCC. In contrast, p16PM did not show
a similar proﬁle suggesting that p14 and p16 are regulated by
different promoters [29].
Our results show an increasing frequency of p16 PM from
NHT to HCC which is in agreement with the some previous
studies of Vivekanandan and Torbenson [30].Similar to p14, O6MGMT plays an important role in cyto-
protection by preventing DNA damage and triggering DNA
repair mechanisms [31]. Because O6MGMT methylation is a
hallmark of speciﬁc cancers, it is perhaps not surprising to ﬁnd
a consistent PM in O6MGMT in both CH and HCC tissues.
Our results show a signiﬁcant increase in the frequency of
O6MGMTPM from CH (26%) to HCC (67.7%) providing
an evidence that this gene could differentiate between CH
and HCC. Literature reviews also revealed varied frequencies
of O6MGMT PM in HCC ranging from 0% [32], to 22–39%
[33]. The variability in the results could be attributed to several
factors including the sensitivity of the PCR, the primer se-
quences and the differences in CpG sites, the etiological factors
contributing to HCC and the geographical differences. The sig-
niﬁcant association reported here between O6MGMT hyper-
methylation and HCV infection is also comparable to
previously published data [22,33].
Our results also show a signiﬁcant difference in the methyl-
ation frequency of APC and CDH1 between CH and HCC
cases where APC was more frequent in the ﬁrst group and
CDH1 in the second group. Methylation of APC and CDH1
genes has been previously reported by Yang et al. [28] who
demonstrated that PM of APC and CDH1 are more frequent
in HBV- and HCV-positive HCC than in HBV- and HCV-
negative cases. PM of these genes was also reported by other
investigators [34]. Nomoto et al. [32] reported APC PM in
88.2% of the NHT compared to 21.6% in chronic hepatitis
with cirrhosis and 82.4% in HCC. They claimed that loss of
APC in cirrhotic and inﬂammatory cases could possibly be
attributed to the presence of inﬂammatory cells and ﬁbroblasts.
In contrast, we reported a high methylation frequency of the
APCPM in CH patients, both in blood and tissues. The differ-
ence between our results and those of Nomoto et al. [32] could
be attributed to (a) their smaller sample size (19 cases); (b) sam-
ples of CH and cirrhosis were obtained from the HCC cases and
not from separate patients or (c) a possibly different etiology
since viral infection was not mentioned in their study.
Finally, PM of thep73 was also reported in 83.9% of the
HCC cases assessed in the current study compared to 21.1%
of CH and none of the NHT. Thus p73 PM could be used to
differentiate between CH and HCC cases even in patient’s
blood. PM of the p73 was reported in some previous studies
on HCC and CH [34].Conclusion
We conclude that aberrant DNA PM of multiple cancer-re-
lated genes is associated with different stages of disease pro-
gression from hepatitis to HCC since PM of p73, p14, O6-
MGMT was associated with HCC whereas aberrant PM of
APC was more common in CH. APC PM could be used as a
maker for early detection of HCV-induced chronic active hep-
atitis. In our study the (APC, p73, p14, O6-MGMT) panel
independently affected the classiﬁcation of cases into HCC
and CH with high accuracy (89.9%), sensitivity (83.9%) and
speciﬁcity (94.7%). Moreover, detection of PM of certain
genes in PBL is a highly sensitive and speciﬁc, noninvasive
indicates that blood could be used, as efﬁciently as tissue biop-
sies, to assess PM which could help in the follow-up of chronic
hepatitis patients and possibly for early detection of HCC,
especially when using well-selected panel.
MGMTAPC
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
(I)
(J)
Fig. 6 (A) Normal hepatic tissue sample showing positive cytoplasmic immunostaining for APC (X200) B: A case of HCV induced
chronic hepatitis showing mild focal cytoplasmic immunostaining for APC (X100). C: A case of HCV induced chronic hepatitis with
cirrhosis negative for APC (X100). D: A case of HCV-associated HCC negative for APC (X100). E: A case of HCV-associated HCC with
positive cytoplasmic immunostaining for APC (X40). (F) Normal hepatic tissue negative for MGMT (X100). (G): A case of HCV-induced
chronic hepatitis with cirrhosis negative for MGMT (X100). (H) A case of HCV-induced chronic hepatitis with cirrhosis positive for
MGMT immunostaining (X100). (I) A case of HCV-induced HCC with marked cytoplasmic immunostaining for MGMT(X200). (J) A
case of HCV-induced HCC showing faint cytoplasmic immunostaining for MGMT(X200).
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40 A.-R.N. Zekri et al.To study the combined effect of the different markers on
the diagnosis of HCC compared to CAH. All signiﬁcant vari-
ables were entered into the stepwise logistic regression. The
above variables are the ones which independently affects the
classiﬁcation of cases into HCC and CAH. These four vari-
ables combined will give an accuracy of 89.9%, sensitivity
83.9% and speciﬁcity 94.7%.
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